TITLE

Evaluation of Therapeutic Response of Patients with Erectile Dysfunction

AUTHOR(S)
Junuzovic, Dzelaludin; Bajramovic, Sejfudin
PUB. DATE
December 2009
SOURCE
Medicinski Arhiv;2009, Vol. 63 Issue 5, p278
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: All three phosphodiesterase-5 (PDE5) inhibitors for the treatment of the erectile dysfunction have similar efficacy and toxicity profiles. Sildenafil and vardenafil have similar molecular structures, but tadalafil is structurally different, which is reflected in its pharmacokinetic profile. These pharmacokinetic differences among the PDE5 inhibitors may underlie patient preference, an important and emerging aspect of ED therapy. Aim: The study is conducted to show and compare efficacy and safety of the three PDE-5 inhibitors and to assess patient's preference in the treatment of erectile dysfunction. It's still unknown which of the three PDE-5 inhibitors is used the most. Methods: Study is conducted during two years on 53 patients with erectile dysfunction. Evaluation is done after 8 weeks of initial treatment followed by a 1-week washout period and then continued the therapy with the second and third medicine by the same protocol. Results: After three months of the treatment, patients' preference was as follows: 33 patients (62%) choose tadalafil, 13 patients (24%) choose sildenafil and 7 patients (14%) choose vardenafil. Choice of PDE-5 for initial treatment was a significant predictor for substitution from one drug to another. Conclusion: Frequency of sexual intercourse (occasional use or regular therapy) and personal experience will determine the medicine of choice. When choosing medicine, attention should be paid to the beginning of its functioning, duration and possible interaction with food.
ACCESSION #
47436249

 

Related Articles

  • Sildenafil or Vardenafil Nonresponders' Erectile Response to Tadalafil. Ozgur, B. C.; Gonenc, F.; Yazicioglu, A. H. // Urology Journal;Oct2009, Vol. 6 Issue 4, p267 

    Introduction: Erectile dysfunction has usually been treated by a phosphodiesterase 5 inhibitor in men, especially in the past decade. Although sildenafil and vardenafil are widely used, there is a high percentage of people who do not respond to these drugs. This study was performed in order to...

  • No long-term effects seen with erectile dysfunction drug. Charters, Lynda; Marmor, Michael F. // Ophthalmology Times;04/15/2001, Vol. 26 Issue 8, p28 

    Reports on a deal of publicity received by sildenafil for its therapeutic action of improving erectile dysfunction and its effects on vision. Mechanism of sildenafil and how it affects the eye; Most striking clinical symptom with sildenafil; Reason sildenafil is not likely to pose a risk for...

  • Valuing the effects of sildenafil in erectile dysfunction. Freemantle, Nick // BMJ: British Medical Journal (International Edition);04/29/2000, Vol. 320 Issue 7243, p1156 

    Evaluates the cost-effectiveness of sildenafil in erectile dysfunction in men. Comparison of the drug with papaverine-phentolamine injections; Assumptions and practical problems associated with generating utility values; Restoration of sexual function with the drug; Acceptance of sildenafil in...

  • Viagra: On release. Gregoire, Alain // BMJ: British Medical Journal (International Edition);09/19/98, Vol. 317 Issue 7161, p759 

    Provides an overview of the effectiveness of Viagra (sildenafil). Sildenafil's specificity of action; The most common side effects; The need for the medical profession to respond with acceptable standards of assessment, followed by regular monitoring of continued effectiveness, appropriateness,...

  • Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. Sairam, Krishnamurthy; Kulinskaya, Elena; Hanbury, Damian; Boustead, Gregory; McNicholas, Thomas // BMC Urology;2002, Vol. 2, p4 

    Introduction: Sildenafil (Viagra®) is one of the drugs used in the first line therapy of male erectile dysfunction (MED). We have recorded outcomes, adverse events and acceptability of Sildenafil (Viagra) therapy in an unselected group of men presenting with ED to a British district general...

  • Erection problems, their causes and their treatment. Chua, Philip S. // Filipino Reporter;8/31/2012, Vol. 40 Issue 39, p39 

    The article discusses the causes and treatment of erectile dysfunction (ED). It defines ED as the diminished or ineffective erection in a man which causes inability to have a successful intercourse 75% of the time. Causes of ED cited include unhealthy lifestyle, drugs such as tranquilizers and...

  • Editorial Commentary. Manganiello, Vincent // International Journal of Impotence Research;Jun2004 Supplement 1, Vol. 16, pS1 

    Comments on the emergence and success of cyclic nucleotide phosphodiesterase inhibitors as effective drug for erectile dysfunction therapy in the U.S. Side effects of the drug; Safety and efficacy of the drug; Discussion of the various aspects of the biology and pharmacology of the drug.

  • Sildenafil Citrate (VIAGRA) Improves Erectile Function in Elderly Patients With Erectile Dysfunction: A Subgroup Analysis. Wagner, Gorm; Montorsi, Francesco; Auerbach, Stephen; Collins, Michael // Journals of Gerontology Series A: Biological Sciences & Medical ;Feb2001, Vol. 56 Issue 2, pM113 

    Presents information on a study which assessed the efficacy and safety of oral sildenafil or Viagra for treating erectile dysfunction in elderly men. Study design and patient selection; Efficacy assessments; Adverse effects of Viagra; Tolerability of sildenafil in elderly patients.

  • Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. Moore, R. A.; Edwards, J. E.; McQuay, H. J. // BMC Urology;2002, Vol. 2, p6 

    Background: Evaluation of company clinical trial reports could provide information for metaanalysis at the commercial introduction of a new technology. Methods: Clinical trial reports of sildenafil for erectile dysfunction from September 1997 were used for meta-analysis of randomised trials (at...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics